UNASSIGNED: Screening recommendations for @entity263 remain controversial, and no specific guidelines exist for screening in renal transplant candidates. To examine whether the use of @entity1486 (PSA)-based screening in @entity1 with @entity454 affects time to transplantation and transplant outcomes, we retrospectively analyzed 3782 male @entity1 >= 18 years of age undergoing primary renal transplant evaluation during a 10-year period. @entity1 were grouped by age per American Urological Association screening guidelines: group 1, @entity1 <55 years; group 2, @entity1 55-69 years; and group 3, @entity1 >69 years. A positive screening test result was defined as a PSA level >4 ng/ml. We used univariate analysis and Cox proportional hazards models to identify the independent effect of screening on transplant waiting times, @entity1 survival, and graft survival. Screening was performed in 63.6% of candidates, and 1198 candidates (31.7%) received kidney transplants. PSA screening was not associated with improved @entity1 survival after transplantation (P=0.24). However, it did increase the time to listing and transplantation for candidates in groups 1 and 2 who had a positive screening result (P<0.05). Furthermore, compared with candidates who were not screened, PSA-screened candidates had a reduced likelihood of receiving a transplant regardless of the screening outcome (P<0.001). These data strongly suggest that PSA screening for @entity263 may be more harmful than protective in renal transplant candidates because it does not appear to confer a survival benefit to these candidates and may delay listing and decrease transplantation rates.

Utility of XXXX Screening in Kidney Transplant Candidates.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen'] @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
